BioNTech SE
BNTX News Today: Stay Updated with the Latest BioNTech SE News in Real Time
Find BNTX news now at Meyka AI. Stay informed with the latest BioNTech SE stocks updates, including price news, market analysis, and expert insights.
BNTX Analyst Rating Maintained at Overweight by Morgan Stanley
Morgan Stanley maintains BNTX analyst rating at Overweight, raises price target to $126 on April 10, 2026.
BNTX Stock Today: March 31: ELCC Cancer Data Steady Amid Biotech Rout
BioNTech stock holds near $85 as biotech volatility hits peers. ELCC cancer data on gotistobart showed 54% lower death risk in advanced lung cancer, supporting medium-term catalysts for German traders
BNTX Stock Today: March 30 — ELCC Data Show 54% Lower Death Risk
BioNTech stock: ELCC 2026 data show 54% lower death risk in advanced lung cancer. What it means for German investors, valuation, catalysts, and technicals.
Top 10 Stocks to Buy or Sell Today as Market Volatility Rises
Global stocks market are showing strong volatility in March 2026 as traders digest conflicting signals from geopolitical tensions, rising energy prices, and economic data. The CBOE Volatility Index (VIX), often called Wall Street’s fear gauge, swung sharply this week, jumping above key levels then retreating as markets tried to regain balance. This turbulence is influencing…
BNTX BioNTech SE March 11, 2026 BMO Maintains Outperform
BNTX analyst rating: BMO maintains Outperform March 11, 2026 and lowers price target to $128
BNTX Stock Today: Founders to Exit; PT Cut to $167 – March 12
BNTX stock today: founders to exit by 2026 and Clear Street cuts price target to $167. What this means for leadership, IP, valuation, mRNA pipeline, and key trading levels for German investors.
Pre-market: BioNTech (22UA.F XETRA) down 17.09% to €72.05: outlook under pressure
Pre-market top loser 22UA.F stock falls to €72.05 on XETRA; analysis of drivers, valuation, and Meyka AI forecasts
Morgan Stanley Maintains Overweight Buy on BioNTech SE (BNTX) March 10, 2026
Morgan Stanley maintained ratings on BioNTech SE. Read implications for BNTX analyst rating and Meyka grade B+
BNTX Stock Today, March 10: Founders Exit; Shares Drop 10% on Shock News
BNTX stock today slumps after founders plan exit by end-2026 to start a new mRNA venture. We cover the mRNA licensing deal, share price reaction, and what to watch next.